Catherine R. Buck has been appointed director of manufacturing at OsoBio. Ms. Buck is responsible for ensuring operations comply with cGMP as they apply to the manufacture of injectable sterile liquid, suspension and lyophilized pharmaceutical products. Additionally, she will ensure compliance with appropriate FDA regulations, and direct manufacturing activities.
Ms. Buck has more than 20 years of leadership and project management experience within the pharmaceutical, medical device and construction industries, and has managed multiple commercial and clinical pharmaceutical manufacturing plants. Her experience includes the start up, process, equipment and facility validation of a new Amgen manufacturing plant that produced Epogen, as well as obtaining FDA approval of automated equipment and software, and preparing for inspection. Ms. Buck also has managed manufacturing facility operations for Johnson & Johnson and Siemens.
“The same continuous improvement expectations that bear on just about every aspect of industrial productivity exist within pharmaceutical manufacturing as well,” said Milton Boyer, president of OsoBio. “We are fortunate to add someone with Catherine’s breadth of experience to lead a manufacturing team that keeps OsoBio competitive without sacrificing our commitment to quality and cGMP compliance.”